Why did Pfizer raise EPS guidance while revenue guidance was unchanged?

The EPS raise reflects strong year-to-date performance, favorable foreign exchange, cost improvement initiatives, and a lower expected effective tax rate (about 13% versus 15% previously). Lower SI&A and R&D expense guidance also contributed. These factors more than offset the approximately $0.20 one-time impact from the 3SBio acquired IPR&D charge expected in Q3 2025.

What is the impact of the 3SBio transaction on Pfizer's financials?

Pfizer will record a one-time $1.35 billion acquired in-process R&D charge in Q3 2025, which is expected to reduce Adjusted diluted EPS by about $0.20. The deal grants Pfizer global ex-China rights to SSGJ-707, a PD-1/VEGF bispecific antibody, with a $1.25 billion upfront payment to 3SBio and up to $4.8 billion in milestones, plus a $100 million China option payment and a $100 million equity investment.

Why are Pfizer's reported and Adjusted EPS so different in Q2 2025?

Reported diluted EPS of $0.51 excludes amortization of intangible assets, acquisition-related items, and certain significant items, which are added back to reach Adjusted EPS of $0.78. The largest add-backs include $1.21 billion of intangible amortization and $422 million in certain legal matters. Reported Other income also benefited from $75 million in net gains on equity securities, which are excluded from Adjusted results.

Is Pfizer returning capital to shareholders through buybacks?

Not currently. Pfizer has made no share repurchases in 2025 and its guidance assumes none for the year. Management said it intends to continue de-levering prudently and to preserve flexibility for value-creating business development deals, with buybacks remaining an option later. Dividends of $4.9 billion ($0.86 per share) were paid in the first half of 2025.

What are the main risks to Pfizer's revenue outlook?

Key risks include about $0.5 billion of unfavorable revenue impact from generic and biosimilar competition, higher Medicare Part D manufacturer discounts under the Inflation Reduction Act, potential pricing changes following the July 31, 2025 presidential letter, tariffs on imports from China, Canada, and Mexico, and declining demand for COVID-19 products, which Pfizer notes is endemic and seasonal. Ibrance, which fell 8% operationally in Q2, illustrates erosion risk from generics.

PFE 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed August 5, 2025. Cited figures are marked; the original filing is the authoritative source.

Pfizer reported second-quarter 2025 results on August 5, 2025, with revenues of $14.7 billion^a, up 10% on an operational basis, driven by strong growth in Vyndaqel family, Comirnaty, Paxlovid, Padcev, Abrysvo, and Lorbrena, partially offset by Ibrance declines and higher IRA-related Medicare Part D manufacturer discounts.

Reported diluted EPS was $0.51^b versus $0.01 a year earlier, while Adjusted diluted EPS rose 30% to $0.78. Reported results benefited from net gains on equity securities and lower interest expense, and Pfizer's cost discipline showed through lower SI&A (down 8%) and R&D (down 8%) spending. Management reaffirmed full-year 2025 revenue guidance of $61.0 to $64.0 billion and raised Adjusted diluted EPS guidance by $0.10 at the midpoint to $2.90 to $3.10.

The raise absorbs a one-time approximately $0.20^c EPS charge from a $1.35 billion acquired IPR&D charge tied to the 3SBio licensing agreement, which will be recorded in Q3 2025. The guidance also reflects a lower assumed effective tax rate of approximately 13% (previously 15%) and reduced SI&A and R&D expense ranges, and it absorbs tariff impacts and potential pricing changes following a July 31, 2025 letter from President Trump. Capital allocation remains focused on de-leveraging and reinvestment.

Pfizer paid $4.9 billion^d in dividends in the first half of 2025 and has made no share repurchases this year, with guidance assuming none for the full year, leaving $3.3 billion of remaining authorization. The company also reiterated its target of approximately $7.2 billion in net cost savings by the end of 2027. Investors should note the Q3 3SBio charge, continued pressure from IRA pricing and generic/biosimilar erosion, and the reliance on COVID-19 products whose demand remains seasonal and uncertain.

02—Key points

Key Highlights

Q2 2025 revenues of $14.7 billion, up 10% operationally, with strong contributions from Vyndaqel family (+21%), Comirnaty (+95%), Paxlovid (+71%), and Padcev (+38%)
Reported diluted EPS of $0.51 vs. $0.01 in Q2 2024; Adjusted diluted EPS of $0.78, up 30% year-over-year
Full-year 2025 revenue guidance reaffirmed at $61.0 to $64.0 billion
Adjusted diluted EPS guidance raised by $0.10 at midpoint to $2.90 to $3.10, despite a one-time ~$0.20 hit from the $1.35 billion 3SBio acquired IPR&D charge in Q3 2025
Effective tax rate guidance lowered to approximately 13% from 15%, and SI&A and R&D expense guidance reduced
No share repurchases in 2025 to date or assumed in guidance; $3.3 billion repurchase authorization remains; $4.9 billion paid in dividends in H1 2025
Reiterated ~$7.2 billion in anticipated net cost savings by end of 2027; Q2 SI&A down 8% and R&D down 8% operationally

03—Questions

Frequently Asked Questions

Why did Pfizer raise EPS guidance while revenue guidance was unchanged?
The EPS raise reflects strong year-to-date performance, favorable foreign exchange, cost improvement initiatives, and a lower expected effective tax rate (about 13% versus 15% previously). Lower SI&A and R&D expense guidance also contributed. These factors more than offset the approximately $0.20 one-time impact from the 3SBio acquired IPR&D charge expected in Q3 2025.
What is the impact of the 3SBio transaction on Pfizer's financials?
Pfizer will record a one-time $1.35 billion acquired in-process R&D charge in Q3 2025, which is expected to reduce Adjusted diluted EPS by about $0.20. The deal grants Pfizer global ex-China rights to SSGJ-707, a PD-1/VEGF bispecific antibody, with a $1.25 billion upfront payment to 3SBio and up to $4.8 billion in milestones, plus a $100 million China option payment and a $100 million equity investment.
Why are Pfizer's reported and Adjusted EPS so different in Q2 2025?
Reported diluted EPS of $0.51 excludes amortization of intangible assets, acquisition-related items, and certain significant items, which are added back to reach Adjusted EPS of $0.78. The largest add-backs include $1.21 billion of intangible amortization and $422 million in certain legal matters. Reported Other income also benefited from $75 million in net gains on equity securities, which are excluded from Adjusted results.
Is Pfizer returning capital to shareholders through buybacks?
Not currently. Pfizer has made no share repurchases in 2025 and its guidance assumes none for the year. Management said it intends to continue de-levering prudently and to preserve flexibility for value-creating business development deals, with buybacks remaining an option later. Dividends of $4.9 billion ($0.86 per share) were paid in the first half of 2025.
What are the main risks to Pfizer's revenue outlook?
Key risks include about $0.5 billion of unfavorable revenue impact from generic and biosimilar competition, higher Medicare Part D manufacturer discounts under the Inflation Reduction Act, potential pricing changes following the July 31, 2025 presidential letter, tariffs on imports from China, Canada, and Mexico, and declining demand for COVID-19 products, which Pfizer notes is endemic and seasonal. Ibrance, which fell 8% operationally in Q2, illustrates erosion risk from generics.

04—Continue

← View all 8-K filings